Posters & Presentations

Scientific Posters and Presentations

Use the search tool to explore publications, posters and presentations and take a deep dive into our leadership in serious cardiovascular diseases.

In July 2026, Servier acquired Edgewise’s muscular dystrophy business, including sevasemten. To support patients, researchers, and healthcare professionals, sevasemten-related posters, presentations, and publications will remain accessible on this page for a limited time.

Cardiovascular

November 2024

American Heart Association Scientific Sessions 2024

Chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucatan mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Post-Exercise Biomarkers of Muscle Injury are Reduced by Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Protein Biomarkers of Muscle Injury Exhibit Differential Reduction with Subject Age in Adults with Becker Muscular Dystrophy

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Clinical Trial Readiness in a Rare and Underserved Disease: Learnings from Community Engagement and the Lived Experience in Becker Muscular Dystrophy (Becker)

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy Results in Reduced Muscle Damage Biomarkers and Functional Stabilization

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD)

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Exploring the Content Validity of Patient-Reported Outcome (PRO) Measures to Capture the Patient Experience of Becker Muscular Dystrophy (BMD)

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Rasch Evaluation of North Star Ambulatory Assessment and North Star Assessment for Limb-Girdle Type Muscular Dystrophies in Becker Muscular Dystrophy

View Poster

Muscular Dystrophy

October 2024

World Muscle Society 2024

Understanding disease progression of Becker muscular dystrophy and a potential novel agent to protect muscle

View Presentation

Posters & Presentations

Chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucatan mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy

Post-Exercise Biomarkers of Muscle Injury are Reduced by Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy

Protein Biomarkers of Muscle Injury Exhibit Differential Reduction with Subject Age in Adults with Becker Muscular Dystrophy

Clinical Trial Readiness in a Rare and Underserved Disease: Learnings from Community Engagement and the Lived Experience in Becker Muscular Dystrophy (Becker)

Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy Results in Reduced Muscle Damage Biomarkers and Functional Stabilization

Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD)

Exploring the Content Validity of Patient-Reported Outcome (PRO) Measures to Capture the Patient Experience of Becker Muscular Dystrophy (BMD)

Rasch Evaluation of North Star Ambulatory Assessment and North Star Assessment for Limb-Girdle Type Muscular Dystrophies in Becker Muscular Dystrophy

Understanding disease progression of Becker muscular dystrophy and a potential novel agent to protect muscle

Footer

In the Clinic